|
GB581334A
(en)
|
1943-09-29 |
1946-10-09 |
Francis Henry Swinden Curd |
New pyrimidine compounds
|
|
JPS4921149B1
(https=)
|
1970-12-28 |
1974-05-30 |
|
|
|
JPS4921148B1
(https=)
|
1970-12-28 |
1974-05-30 |
|
|
|
DE2341925A1
(de)
|
1973-08-20 |
1975-03-06 |
Thomae Gmbh Dr K |
Neue pyrimidinderivate und verfahren zu ihrer herstellung
|
|
AT340933B
(de)
|
1973-08-20 |
1978-01-10 |
Thomae Gmbh Dr K |
Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
|
|
US4994386A
(en)
|
1987-07-13 |
1991-02-19 |
Pharmacia Diagnostics, Inc. |
Production of HBLV virus in the HSB-2 cell line
|
|
US4929726A
(en)
|
1988-02-09 |
1990-05-29 |
Georgia State University Foundation, Inc. |
Novel diazines and their method of preparation
|
|
EP0330263A1
(en)
|
1988-02-25 |
1989-08-30 |
Merck & Co. Inc. |
Piperazinylalkylpyrimidines as hypoglycemic agents
|
|
GB9012311D0
(en)
|
1990-06-01 |
1990-07-18 |
Wellcome Found |
Pharmacologically active cns compounds
|
|
CA2065443A1
(en)
|
1990-07-03 |
1992-01-04 |
Akira Mizuchi |
Pyrimidine compound and pharmaceutically acceptable salts thereof
|
|
KR100275300B1
(ko)
|
1995-04-13 |
2000-12-15 |
고바야시 유키오 |
신규 4,6-디아릴피리미딘 유도체 및 그 염(novel 4,6-diarylpyrimidine derivatives and salts thereof)
|
|
JP3734907B2
(ja)
|
1996-12-19 |
2006-01-11 |
富士写真フイルム株式会社 |
現像処理方法
|
|
CN1129597C
(zh)
|
1997-07-24 |
2003-12-03 |
全药工业株式会社 |
杂环化合物和以其为有效成分的抗肿瘤剂
|
|
JPH11158073A
(ja)
|
1997-09-26 |
1999-06-15 |
Takeda Chem Ind Ltd |
アデノシンａ３拮抗剤
|
|
US6440965B1
(en)
|
1997-10-15 |
2002-08-27 |
Krenitsky Pharmaceuticals, Inc. |
Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
|
|
US6150362A
(en)
|
1997-12-12 |
2000-11-21 |
Henkin; Jack |
Triazine angiogenesis inhibitors
|
|
EP0930302B1
(en)
|
1998-01-16 |
2003-04-02 |
F.Hoffmann-La Roche Ag |
Benzosulfone derivatives
|
|
WO1999065897A1
(en)
|
1998-06-19 |
1999-12-23 |
Chiron Corporation |
Inhibitors of glycogen synthase kinase 3
|
|
US7045519B2
(en)
|
1998-06-19 |
2006-05-16 |
Chiron Corporation |
Inhibitors of glycogen synthase kinase 3
|
|
US6495558B1
(en)
|
1999-01-22 |
2002-12-17 |
Amgen Inc. |
Kinase inhibitors
|
|
CA2359680A1
(en)
|
1999-01-22 |
2000-07-27 |
David M. Armistead |
Kinase inhibitors
|
|
EP1194152A4
(en)
|
1999-06-30 |
2002-11-06 |
Merck & Co Inc |
Links to SRC kinase inhibition
|
|
WO2001000213A1
(en)
|
1999-06-30 |
2001-01-04 |
Merck & Co., Inc. |
Src kinase inhibitor compounds
|
|
EP1206260A4
(en)
|
1999-06-30 |
2002-10-30 |
Merck & Co Inc |
SRC-KINASE INHIBITING COMPOUNDS
|
|
AU777735B2
(en)
|
1999-07-15 |
2004-10-28 |
Pharmacopeia, Inc. |
Bradykinin B1 receptor antagonists
|
|
JP2001089452A
(ja)
|
1999-09-22 |
2001-04-03 |
Sankyo Co Ltd |
ピリミジン誘導体
|
|
AU3704101A
(en)
|
2000-02-17 |
2001-08-27 |
Amgen Inc |
Kinase inhibitors
|
|
CN100355751C
(zh)
|
2000-03-29 |
2007-12-19 |
西克拉塞尔有限公司 |
2－取代的4－杂芳基－嘧啶、其组合物及其用途
|
|
KR100774855B1
(ko)
|
2000-04-27 |
2007-11-08 |
아스텔라스세이야쿠 가부시키가이샤 |
축합 헤테로아릴 유도체
|
|
CN1657523A
(zh)
|
2000-04-28 |
2005-08-24 |
田边制药株式会社 |
环状化合物
|
|
WO2002000647A1
(en)
|
2000-06-23 |
2002-01-03 |
Bristol-Myers Squibb Pharma Company |
Heteroaryl-phenyl substituted factor xa inhibitors
|
|
AU9502601A
(en)
|
2000-09-06 |
2002-03-22 |
Chiron Corp |
Inhibitors of glycogen synthase kinase 3
|
|
WO2002022605A1
(en)
|
2000-09-15 |
2002-03-21 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
SE0004053D0
(sv)
|
2000-11-06 |
2000-11-06 |
Astrazeneca Ab |
N-type calcium channel antagonists for the treatment of pain
|
|
US6989385B2
(en)
|
2000-12-21 |
2006-01-24 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
WO2002062766A2
(en)
|
2001-02-07 |
2002-08-15 |
Millennium Pharmaceuticals, Inc. |
Melanocortin-4 receptor binding compounds and methods of use thereof
|
|
AU2002258400A1
(en)
|
2001-02-16 |
2002-08-28 |
Tularik Inc. |
Methods of using pyrimidine-based antiviral agents
|
|
EP1395561A1
(en)
|
2001-05-25 |
2004-03-10 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Carbamate and oxamide compounds as inhibitors of cytokine production
|
|
CA2450934A1
(en)
|
2001-06-19 |
2002-12-27 |
Marco Dodier |
Pyrimidine inhibitors of phosphodiesterase (pde) 7
|
|
US6603000B2
(en)
|
2001-07-11 |
2003-08-05 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Synthesis for heteroarylamine compounds
|
|
WO2003030909A1
(en)
|
2001-09-25 |
2003-04-17 |
Bayer Pharmaceuticals Corporation |
2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
|
|
US20040009981A1
(en)
|
2002-03-15 |
2004-01-15 |
David Bebbington |
Compositions useful as inhibitors of protein kinases
|
|
DE60332433D1
(de)
|
2002-03-15 |
2010-06-17 |
Vertex Pharma |
Azolylaminoazine als proteinkinasehemmer
|
|
EP1485381B8
(en)
|
2002-03-15 |
2010-05-12 |
Vertex Pharmaceuticals Incorporated |
Azolylaminoazine as inhibitors of protein kinases
|
|
US6846928B2
(en)
|
2002-03-15 |
2005-01-25 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
|
US20040082627A1
(en)
|
2002-06-21 |
2004-04-29 |
Darrow James W. |
Certain aromatic monocycles as kinase modulators
|
|
JP2006510597A
(ja)
|
2002-09-27 |
2006-03-30 |
メルク エンド カムパニー インコーポレーテッド |
置換ピリミジン類
|
|
US20040171073A1
(en)
|
2002-10-08 |
2004-09-02 |
Massachusetts Institute Of Technology |
Compounds for modulation of cholesterol transport
|
|
US7223870B2
(en)
|
2002-11-01 |
2007-05-29 |
Pfizer Inc. |
Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
|
|
EA013811B1
(ru)
|
2002-11-21 |
2010-08-30 |
Новартис Вэксинес Энд Дайэгностикс, Инк. |
2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
|
|
JP2007524596A
(ja)
|
2003-02-28 |
2007-08-30 |
トランスフォーム・ファーマシューティカルズ・インコーポレイテッド |
共結晶医薬組成物
|
|
JP2006521357A
(ja)
|
2003-03-24 |
2006-09-21 |
メルク エンド カムパニー インコーポレーテッド |
ナトリウムチャンネル遮断薬としてのビアリール置換６員複素環化合物
|
|
US20050014753A1
(en)
|
2003-04-04 |
2005-01-20 |
Irm Llc |
Novel compounds and compositions as protein kinase inhibitors
|
|
JP4895806B2
(ja)
|
2003-04-09 |
2012-03-14 |
エクセリクシス， インク． |
Ｔｉｅ−２モジュレータと使用方法
|
|
CA2531490A1
(en)
|
2003-07-15 |
2005-02-03 |
Neurogen Corporation |
Substituted pyrimidin-4-ylamina analogues as vanilloid receptor ligands
|
|
CA2531619A1
(en)
|
2003-07-16 |
2005-01-27 |
Neurogen Corporation |
Biaryl piperazinyl-pyridine analogues
|
|
AR045944A1
(es)
*
|
2003-09-24 |
2005-11-16 |
Novartis Ag |
Derivados de isoquinolina 1.4-disustituidas
|
|
CA2561895A1
(en)
|
2004-04-13 |
2005-10-27 |
Icagen, Inc. |
Polycyclic pyrimidines as potassium ion channel modulators
|
|
GB0415364D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
GB0415365D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
MY145822A
(en)
|
2004-08-13 |
2012-04-30 |
Neurogen Corp |
Substituted biaryl piperazinyl-pyridine analogues
|
|
JP2008521900A
(ja)
*
|
2004-11-30 |
2008-06-26 |
アムジエン・インコーポレーテツド |
キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用
|
|
CA2590586A1
(en)
|
2004-12-13 |
2006-07-06 |
Neurogen Corporation |
Substituted biaryl analogues
|
|
WO2006065872A1
(en)
|
2004-12-13 |
2006-06-22 |
Neurogen Corporation |
Piperazinyl-pyridine analogues
|
|
ES2382068T3
(es)
|
2004-12-28 |
2012-06-05 |
Kinex Pharmaceuticals, Llc |
Composiciones y métodos para tratar trastornos de proliferación celular
|
|
WO2006078992A2
(en)
|
2005-01-19 |
2006-07-27 |
Neurogen Corporation |
Heteroaryl substituted piperazinyl-pyridine analogues
|
|
CA2599320A1
(en)
|
2005-02-25 |
2006-08-31 |
Kudos Pharmaceuticals Limited |
Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
|
|
TW200716594A
(en)
|
2005-04-18 |
2007-05-01 |
Neurogen Corp |
Substituted heteroaryl CB1 antagonists
|
|
GB2431156A
(en)
|
2005-10-11 |
2007-04-18 |
Piramed Ltd |
1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
|
|
EP1979325A1
(en)
|
2006-01-11 |
2008-10-15 |
AstraZeneca AB |
Morpholino pyrimidine derivatives and their use in therapy
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
EP2012794B1
(en)
*
|
2006-04-13 |
2014-09-17 |
The Trustees of Columbia University in the City of New York |
Compositions and intraluminal devices for inhibiting vascular stenosis
|
|
TW200833342A
(en)
|
2006-12-28 |
2008-08-16 |
Basf Ag |
2-substituted pyrimidines I in therapy
|
|
WO2008098058A1
(en)
|
2007-02-06 |
2008-08-14 |
Novartis Ag |
Pi 3-kinase inhibitors and methods of their use
|
|
US7957951B2
(en)
|
2007-03-16 |
2011-06-07 |
Robert Bosch Gmbh |
Address translation system for use in a simulation environment
|
|
AU2008273889B2
(en)
|
2007-07-09 |
2012-03-08 |
Astrazeneca Ab |
Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
|
|
WO2009066084A1
(en)
|
2007-11-21 |
2009-05-28 |
F. Hoffmann-La Roche Ag |
2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
|
|
US20110033453A1
(en)
|
2008-03-05 |
2011-02-10 |
Carlos Garcia-Echeverria |
Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
|
|
KR20100126553A
(ko)
|
2008-03-26 |
2010-12-01 |
노파르티스 아게 |
Ｖｅｇｆ-유도성 혈관신생 과정의 유력한 조절제로서의 이미다조퀴놀린 및 피리미딘 유도체
|
|
JP2011515462A
(ja)
|
2008-03-27 |
2011-05-19 |
アウククランド ウニセルビセス リミテッド |
置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用
|
|
TW200948362A
(en)
|
2008-04-09 |
2009-12-01 |
Mitsubishi Tanabe Pharma Corp |
New compounds and their uses
|
|
GB0815369D0
(en)
|
2008-08-22 |
2008-10-01 |
Summit Corp Plc |
Compounds for treatment of duchenne muscular dystrophy
|
|
WO2010049481A1
(en)
|
2008-10-31 |
2010-05-06 |
Novartis Ag |
Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
|
|
GB2465405A
(en)
|
2008-11-10 |
2010-05-19 |
Univ Basel |
Triazine, pyrimidine and pyridine analogues and their use in therapy
|
|
US8513242B2
(en)
|
2008-12-12 |
2013-08-20 |
Cystic Fibrosis Foundation Therapeutics, Inc. |
Pyrimidine compounds and methods of making and using same
|
|
US8673891B2
(en)
|
2009-02-06 |
2014-03-18 |
Nippon Shinyaku Co., Ltd. |
Aminopyrazine derivative and medicine
|
|
JP5747440B2
(ja)
|
2009-02-06 |
2015-07-15 |
住友化学株式会社 |
ヒドラジド化合物及びその有害生物防除用途
|
|
US20120121515A1
(en)
|
2009-03-13 |
2012-05-17 |
Lenny Dang |
Methods and compositions for cell-proliferation-related disorders
|
|
WO2010120994A2
(en)
|
2009-04-17 |
2010-10-21 |
Wyeth Llc |
Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
|
|
MX2011012343A
(es)
|
2009-05-19 |
2011-12-14 |
Dow Agrosciences Llc |
Compuestos y metodos para controlar hongos.
|
|
CA2767008C
(en)
|
2009-07-07 |
2018-01-30 |
Pathway Therapeutics, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
|
WO2011017296A1
(en)
|
2009-08-04 |
2011-02-10 |
Schering Corporation |
4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
|
|
AR077999A1
(es)
|
2009-09-02 |
2011-10-05 |
Vifor Int Ag |
Antagonistas de pirimidin y triazin-hepcidina
|
|
JP2013504325A
(ja)
|
2009-09-09 |
2013-02-07 |
アビラ セラピューティクス， インコーポレイテッド |
Ｐｉ３キナーゼインヒビターおよびその使用
|
|
ES2642109T3
(es)
|
2009-12-09 |
2017-11-15 |
Agios Pharmaceuticals, Inc. |
Compuestos terapéuticamente activos para su uso en el tratamiento de cáncer caracterizados por tener una mutación de IDH
|
|
GB201004200D0
(en)
|
2010-03-15 |
2010-04-28 |
Univ Basel |
Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
|
|
US9133123B2
(en)
|
2010-04-23 |
2015-09-15 |
Cytokinetics, Inc. |
Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
|
|
AR081331A1
(es)
|
2010-04-23 |
2012-08-08 |
Cytokinetics Inc |
Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
|
|
AR081626A1
(es)
|
2010-04-23 |
2012-10-10 |
Cytokinetics Inc |
Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
|
|
WO2011143160A2
(en)
|
2010-05-10 |
2011-11-17 |
The Johns Hopkins University |
Metabolic inhibitor against tumors having an idh mutation
|
|
CN103097340B
(zh)
|
2010-07-16 |
2018-03-16 |
安吉奥斯医药品有限公司 |
治疗活性组合物及其使用方法
|
|
SG188439A1
(en)
|
2010-10-01 |
2013-05-31 |
Novartis Ag |
Manufacturing process for pyrimidine derivatives
|
|
SG189019A1
(en)
|
2010-10-18 |
2013-05-31 |
Cerenis Therapeutics Holding Sa |
Compounds, compositions and methods useful for cholesterol mobilisation
|
|
GB201106829D0
(en)
|
2011-04-21 |
2011-06-01 |
Proximagen Ltd |
Heterocyclic compounds
|
|
EP2673268A1
(en)
|
2011-02-11 |
2013-12-18 |
Dana-Farber Cancer Institute, Inc. |
Method of inhibiting hamartoma tumor cells
|
|
CN102827073A
(zh)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
|
WO2013030368A1
(en)
|
2011-09-01 |
2013-03-07 |
Novartis Ag |
Pi3k inhibitor for use in the treatment of bone cancer or for preventing metastatic dissemination primary cancer cells into the bone
|
|
BR112014007310A2
(pt)
|
2011-09-27 |
2017-04-04 |
Novartis Ag |
3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
|
|
AU2012318874A1
(en)
|
2011-10-06 |
2014-05-15 |
Merck Sharp & Dohme Corp. |
1,3-substituted azetidine PDE10 inhibitors
|
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
|
WO2013173283A1
(en)
*
|
2012-05-16 |
2013-11-21 |
Novartis Ag |
Dosage regimen for a pi-3 kinase inhibitor
|
|
RU2014154009A
(ru)
|
2012-06-06 |
2016-08-10 |
Новартис Аг |
Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания
|
|
WO2014028566A1
(en)
|
2012-08-16 |
2014-02-20 |
Novartis Ag |
Combination of pi3k inhibitor and c-met inhibitor
|
|
AU2013336807B2
(en)
|
2012-10-23 |
2016-10-27 |
Novartis Ag |
Improved process for manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine
|
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
|
AU2014229283B2
(en)
|
2013-03-14 |
2016-07-28 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
|
|
JP6387360B2
(ja)
|
2013-03-14 |
2018-09-05 |
ノバルティス アーゲー |
変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
|
|
CN103483345B
(zh)
|
2013-09-25 |
2016-07-06 |
中山大学 |
Pi3k激酶抑制剂、包含其的药物组合物及其应用
|
|
CN103694218B
(zh)
|
2013-12-05 |
2016-04-27 |
中山大学 |
嘧啶化合物、pi3k抑制剂、包含pi3k抑制剂的药物组合物及应用
|